SHENZHEN UNI-MEDICA TECHNOLOGY
LIFE SCIENCE TECHNOLOGY
LIFE SCIENCE TECHNOLOGY
SHENZHEN UNI-MEDICA TECHNOLOGY is a national high-tech enterprise that focuses on the R&D and industrialization of molecular diagnostic products in the Biotechnology and Health Care industries. The company collaborates with esteemed institutions such as the Hong Kong University of Science and Technology, Shenzhen University, and the Chinese Academy of Sciences. It has received recognition as one of the top 100 new Chinese innovative enterprises.
The core driving force of Uni-medica is the technical innovation of molecular detection methods. Their multi-omics technologies, including multiplex PCR, NGS technology, and flow cytometry, are utilized to provide accurate diagnosis of infectious diseases and genetic diseases. The company is ISO 13485 and CFDA qualified, and its pathogen molecular detection products are widely used in hospitals, Centers for Disease Control and Prevention, and Quarantine Laboratories throughout the country.
Founded in 2013, Uni-medica recently received a CNY20.00M corporate round investment from Beijing Leadman Biochemistry on 08 November 2022. This strategic investment is poised to further bolster the company's position in the life science technology sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Corporate Round | CNY20.00M | 1 |
|
08 Nov 2022 |
| Venture Round | Unknown | 1 |
|
20 May 2022 |
No recent news or press coverage available for SHENZHEN UNI-MEDICA TECHNOLOGY .
We care about your data, and we'd love to use cookies make your experience better.